Autoimmunity and cancer rates have both been on the rise in Western civilization prompting many to investigate the link between the two entities. This review will investigate the complex interactions between the activation and deactivation of the immune system and the development of malignancy. Additional focus will be placed on the main classes of immune inhibitor therapy utilized in transplant patients and in autoimmune disease including TNF-alpha, Calcineurin, mTOR, purine synthesis antagonists and IMPDH inhibitors.
Keywords: IMPDH inhibitors; TNF-alpha inhibitors; autoimmunity; calcineurin inhibitors; cancer progression; immune checkpoint inhibitors; immunodeficiency; immunosurveillance; mTOR inhibitors; purine antagonists; transplant.